Literature DB >> 33585001

Assessment of liver cancer biomarkers.

Vahid Mansouri1, Mohhamadreza Razzaghi2, Abdolrahim Nikzamir3, Alireza Ahmadzadeh4, Majid Iranshahi5, Mehrdad Haghazali6, Mostafa Hamdieh7.   

Abstract

Liver cancer is the third cause of cancer-related deaths in the world. It is primarily divides into two main types, namely hepatocellular carcinoma (HC) and cholangiocarcinoma (IC). Due to the increasing number of patients with liver cancer and the high mortality rate, early diagnosis of the disease can be helpful in treatment, but most patients are diagnosed atlate stages of HC. The aim of this study is to screen and provide an overview on candidate biomarkers related to primary liver cancer to introduce the critical ones. In this study, various biomarkers related to the diagnosis of primary liver cancer have been studied. Accordingly, biomarkers are divided into different groups as blood biomarkers classified as serum and plasma biomarkers, tissue biomarkers, microRNA biomarkers, proteomic biomarkers and altered genes. Previous researches have focused on liver cells and bile ducts, the surround cellular environment, how cells differentiate, and the types of genes expressed in liver cancer. Some even have focused on the origin of tumor cells and how they differentiate and develop. In all these studies, the expression of specific proteins and genes in liver cancer has been considered. Based on available sources, biomarkers can be considered as candidates to diagnose and prognosis of various types of primary liver cancer, from sources such as blood, tissue, mic-RNA, proteome and genes. However, more investigations are required to introduce a biomarker for precise detection of early liver cancer. ©2020 RIGLD, Research Institute for Gastroenterology and Liver Diseases.

Entities:  

Keywords:  Biomarker; Diagnosis; Hepatocellular carcinoma; Prognosis; Proteomics

Year:  2020        PMID: 33585001      PMCID: PMC7881406     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol Bed Bench        ISSN: 2008-2258


  98 in total

1.  p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression.

Authors:  Sung-Hwan Moon; Chun-Hao Huang; Shauna L Houlihan; Kausik Regunath; William A Freed-Pastor; John P Morris; Darjus F Tschaharganeh; Edward R Kastenhuber; Anthony M Barsotti; Rachel Culp-Hill; Wen Xue; Yu-Jui Ho; Timour Baslan; Xiang Li; Allison Mayle; Elisa de Stanchina; Lars Zender; David R Tong; Angelo D'Alessandro; Scott W Lowe; Carol Prives
Journal:  Cell       Date:  2018-12-20       Impact factor: 41.582

2.  Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma.

Authors:  Jian Zhou; Lei Yu; Xue Gao; Jie Hu; Jiping Wang; Zhi Dai; Jie-Fei Wang; Zhiyong Zhang; Shaohua Lu; Xiaowu Huang; Zheng Wang; Shuangjian Qiu; Xiaoying Wang; Guohuan Yang; Huichuan Sun; Zhaoyou Tang; Ying Wu; Hongguang Zhu; Jia Fan
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

3.  MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis.

Authors:  Wei-Chih Tsai; Sheng-Da Hsu; Chu-Sui Hsu; Tsung-Ching Lai; Shu-Jen Chen; Roger Shen; Yi Huang; Hua-Chien Chen; Chien-Hsin Lee; Ting-Fen Tsai; Ming-Ta Hsu; Jaw-Ching Wu; Hsien-Da Huang; Ming-Shi Shiao; Michael Hsiao; Ann-Ping Tsou
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

4.  Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms.

Authors:  Benjamin C Yan; Can Gong; Jie Song; Thomas Krausz; Maria Tretiakova; Elizabeth Hyjek; Hikmat Al-Ahmadie; Venancio Alves; Shu-Yuan Xiao; Robert A Anders; John A Hart
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

Review 5.  Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Authors:  Josep M Llovet; Virginia Hernandez-Gea
Journal:  Clin Cancer Res       Date:  2014-03-03       Impact factor: 12.531

Review 6.  Hepatocellualar carcinoma serum markers.

Authors:  Gaetano Bertino; Annalisa Ardiri; Michele Malaguarnera; Giulia Malaguarnera; Nicoletta Bertino; Giuseppe Stefano Calvagno
Journal:  Semin Oncol       Date:  2012-08       Impact factor: 4.929

7.  Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.

Authors:  Hirofumi Shirakawa; Toshimitsu Kuronuma; Yoshiko Nishimura; Takahiro Hasebe; Masayuki Nakano; Naoto Gotohda; Shinichiro Takahashi; Toshio Nakagohri; Masaru Konishi; Nobuaki Kobayashi; Taira Kinoshita; Tetsuya Nakatsura
Journal:  Int J Oncol       Date:  2009-03       Impact factor: 5.650

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography.

Authors:  Rui Li; Dan Yang; Chun-Lin Tang; Ping Cai; Kuan-Sheng Ma; Shi-Yi Ding; Xiao-Hang Zhang; De-Yu Guo; Xiao-Chu Yan
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

10.  TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.

Authors:  Daniel W H Ho; Lo K Chan; Yung T Chiu; Iris M J Xu; Ronnie T P Poon; Tan T Cheung; Chung N Tang; Victor W L Tang; Irene L O Lo; Polly W Y Lam; Derek T W Yau; Miao X Li; Chun M Wong; Irene O L Ng
Journal:  Gut       Date:  2016-12-14       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.